The Manila Times1h
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results ...
STAT1h
As Trump pauses enforcement of an anti-bribery law, will pharma engage in bad behavior?
The Trump administration's decision to pause enforcement of an anti-bribery law raised the specter that drugmakers could engage in bad behavior as a result.
The Manila Times1h
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to use approximately $25 million to ...
Medical Marketing & Media1h
The Escalator: Pfizer, Vertex Pharmaceuticals, Inizio and more
Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.
BioPharma Dive6h
Biogen inks royalty deal to gain funding for lupus drug R&D
The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...
BioSpace8h
Biogen Taps Royalty Pharma for $250M to Power Phase III Lupus Program
The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Royalty Pharma (RPRX), Waters (WAT) and OrganiGram Holdings (OGI)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Royalty Pharma (RPRX – Research Report), ...
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
The USAN designation reflects Okyo Pharma’s commitment to developing new therapies for unmet medical needs in ophthalmology. The suffix “-mod” in urcosimod denotes its classification as a modulator of ...